Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma

George O. Negrea,[1] Rebecca Elstrom,[2] Steven L. Allen,[3] Kanti R. Rai,[4] Rashid M. Abbasi,[5] Charles M. Farber,[6] Nick Teoh,[7] Heather Horne,[7] William A. Wegener,[7] and David M. Goldenberg[7,8]

[1]Low Country Cancer Care Associates, Savannah, GA; [2]Weill Cornell Medical College, New York, NY; [3]North Shore University Hospital, Manhasset, NY; [4]Long Island Jewish Medical Center, New Hyde Park, NY; [5]Hematology Oncology Specialists, Denville, NJ; [6]Carol G. Simon Cancer Center, Morristown, NJ; [7]Immunomedics, Inc., Morris Plains, NJ; and [8]Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ, USA

Citation: Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, and Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica 2011;96(4):567-573. doi:10.3324/haematol.2010.037390

Online Supplementary Table S1. Frequency of all adverse events

	All events (Grade ≥3)	Treatment-related events* (Grade ≥3)
Frequency of patients with:		
Injection site reaction	6 (0)	6 (0)
Pain in extremity	4 (0)	4 (0)
Nausea	3 (0)	3 (0)
Upper respiratory tract infection	3 (0)	1 (0)
Chills	2 (0)	2 (0)
Dyspnea	2 (0)	1 (0)
Tongue disorder	1 (0)	1 (0)
Chest pain	1 (0)	1 (0)
Injection site erythema	1 (0)	1 (0)
Peripheral edema	1 (0)	1 (0)
Pain, general	1 (0)	1 (0)
Arthralgia	1 (0)	1 (0)
Groin pain	1 (0)	1 (0)
Musculoskeletal pain	1 (0)	1 (0)
Pain in arm	1 (0)	1 (0)
Dizziness	1 (0)	1 (0)
Headache	1 (0)	1 (0)
Nasal congestion	1 (0)	1 (0)
Erythema	1 (0)	1 (0)
Pruritis	1 (0)	1 (0)
Lung neoplasm†	1 (1)	0 (0)
Flank pain	1 (0)	0 (0)
Sinusitis	1 (0)	0 (0)
Fever	1 (0)	0 (0)
Insomnia	1 (0)	0 (0)
Cough	1 (0)	0 (0)
Rash	1 (0)	0 (0)

**Considered at least possibly treatment-related. †Present prior to study entry.*

Online Supplementary Table S2. Safety laboratories: percentage change from baseline values (mean ± SD)*

	Injection 2	Injection 3	Injection 4	Week 4	Week 12
Hematology					
Hemoglobin	-0.7 ± 3.1	1.9 ± 7.3	1.4 ± 8.3	1.9 ± 10.2	2.3 ± 9.3
WBC	-0.1 ± 15.8	0.9 ± 19.0	3.6 ± 23.3	-0.3 ± 20.8	-4.4 ± 22.9
ANC	8.2 ± 17.5	9.6 ± 24.1	11.7 ± 27.7	8.3 ± 32.4	-4.4 ± 22.3
Platelets	9.1 ± 22.6	6.2 ± 20.7	6.7 ± 14.7	1.6 ± 15.8	-2.2 ± 13.4
Serum chemistry					
Creatinine	1.7 ± 12.1	3.1 ± 9.0	3.5 ± 11.8	1.9 ± 14.3	9.7 ± 18.3
Total bilirubin	20.8 ± 51.0	17.7± 38.2	14.9 ± 33.1	17.0 ± 38.8	15.4 ± 55.8
Alkaline phosphatase	4.0 ± 17.5	6.6 ± 14.9	3.1 ± 18.5	3.6 ± 20.5	1.5 ± 24.1
SGPT (ALT)	-5.1 ± 20.6	-0.1 ± 17.3	-5.2 ± 19.4	-4.5 ± 27.2	-2.4 ± 19.4
SGOT (AST)	-4.2 ± 18.9	-1.1 ± 39.9	-3.4 ± 14.8	-0.2 ± 30.3	0.6 ± 19.4

**Statistics based on all 17 patients at each time point, except for hematology samples unavailable from one patient at injection 2 and 4 patients at week 12, serum chemistry samples unavailable from 3 patients at week 12, and 2 patients with elevated lymphocyte counts due to leukemic involvement who were excluded just from the WBC statistics.*

Online Supplementary Table S3. Safety laboratories: maximum post-baseline CTC v. 3.0 toxicity grades (N=17)

	Maximum post-baseline grade			
	1*	2†	3	4
Hematology				
Hemoglobin	4	0	0	0
WBC	4	0	0	0
ANC	3	0	0	0
Platelets	0	1	0	0
Serum chemistry				
Creatinine	2	0	0	0
Total bilirubin	0	0	0	0
Alkaline phosphatase	1	0	0	0
SGPT (ALT)	1	0	0	0
SGOT (AST)	1	0	0	0

**These few events predominantly involved baseline laboratory values at or close to Grade 1 levels. †This single event involved baseline Grade 1 platelet levels of 102,000/μL which varied during the study, reaching a borderline Grade 2 value of 74,000/μL on one occasion.*